MedTrace Logo

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

NCT02323178 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-20

No results posted yet for this study

Summary

Treatment of patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia.

Conditions

Interventions

DRUG

eltrombopag

initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Groupe Francophone des Myelodysplasies

    lead OTHER

Principal Investigators

  • Raphaël Itzykson, MD · Saint-Louis Hospital, Paris, France

  • Pierre Fenaux, MD, PHD · Saint-Louis Hospital, Paris, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-07
Primary Completion
2018-12-31
Completion
2021-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323178 on ClinicalTrials.gov